GlassScriptPhysician profile
Steven M Dittes
NPI 1770593089
$574.92
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $95.28 · 2022: $32.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $184.82 | 2019-2020 | |
| Akebia Therapeutics INC | $57.98 | 2019 | |
| Octapharma USA, INC. | $41.42 | 2019 | |
| Insmed, INC. | $32.48 | 2022 | |
| Philips North America LLC | $27.74 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $25.00 | 2020 | |
| Gilead Sciences, INC. | $23.61 | 2019 | |
| Vifor Pharma, INC. | $21.97 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.76 | 2019 | |
| Janssen Biotech, INC. | $19.09 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.36 | 2020 | |
| Astellas Pharma US INC | $18.22 | 2019 | |
| Mayne Pharma Commercial LLC | $17.81 | 2019 | |
| Amgen INC. | $14.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.11 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $12.67 | 2019 | |
| Opko Pharmaceuticals, LLC | $12.43 | 2019 | |
| Travere Therapeutics, INC. | $11.75 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dittes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.